1492 Capital Management’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

1492 Capital Management’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,480	Closed	-$1.33M	–	123
2021 Q3	$1.33M	Buy	14,480 +2,546	+21%	+$263K	0.67%	51
2021 Q2	$1.72M	Buy	11,934 +5,736	+93%	+$1.44M	0.88%	44
2021 Q1	$1.74M	Buy	+6,198	New	+$1.82M	0.99%	39

Other funds holding KRBP

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1492 Capital Management's KRBP Position: Q4 2021 in Review

1492 Capital Management sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2021, closing a stake of 14,480 shares — an estimated $1.33M sold.

1492 Capital Management first reported a position in KRBP in Q1 2021 and held it in 3 quarters. The position peaked at $1.74M in Q1 2021. 20 funds tracked by Wall St. Rank hold KRBP as of Q4 2021.

1492 Capital Management reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
1492 Capital Management sold 14,480 Kiromic BioPharma, Inc. Common Stock shares in Q4 2021, an estimated $1.33M.
1492 Capital Management first reported a position in Kiromic BioPharma, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
1492 Capital Management's Kiromic BioPharma, Inc. Common Stock position peaked at $1.74M in Q1 2021.
20 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2021.

Based on 1492 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.